This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

This study has been completed.
Roche Pharma AG
Information provided by:
Swedish Medical Center Identifier:
First received: April 18, 2006
Last updated: March 4, 2010
Last verified: March 2010
The purpose of this study is to test the effectiveness and safety of the drug combination of gemcitabine and capecitabine (Xeloda) in patients with advanced pancreatic cancer.

Condition Intervention Phase
Pancreatic Cancer Drug: Capecitabine (Xeloda) Drug: Gemcitabine Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of Gemcitabine and Capecitabine (Xeloda) in Patients With Advanced Pancreatic Carcinoma

Resource links provided by NLM:

Further study details as provided by Swedish Medical Center:

Primary Outcome Measures:
  • MTD and DLT for the combination therapy of gemcitabine and capecitabine [ Time Frame: January 2010 ]

Secondary Outcome Measures:
  • Tumor Response [ Time Frame: January 2010 ]

Enrollment: 20
Study Start Date: December 2003
Study Completion Date: August 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Capecitabine (Xeloda)
    650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
    Other Name: Xeloda
    Drug: Gemcitabine
    750 mg/m2 IV Days 1 & 8 q 21 days
    Other Name: Gemzar

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metastatic or unresectable pancreatic cancer
  • No prior chemotherapy except radiation-sensitizing doses of 5-FU
  • No radiotherapy less than 4 weeks prior to the start of the study

Exclusion Criteria:

  • Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to 5-FU
  • Moderate to severe renal impairment
  • Uncontrolled diabetes
  • Inability to swallow tablets
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00316420

United States, Washington
Swedish Medical Center Cancer Institute
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Swedish Medical Center
Roche Pharma AG
Principal Investigator: Philip Gold, MD Swedish Medical Center Cancer Institute
Principal Investigator: Henry Kaplan, MD Swedish Medical Center Cancer Institute
  More Information

Responsible Party: Philip Gold, M.D., Swedish Medical Center, Swedish Cancer Insitute Identifier: NCT00316420     History of Changes
Other Study ID Numbers: TI027 PG/HK
Study First Received: April 18, 2006
Last Updated: March 4, 2010

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017